mRNA 치료 시장 : 유형, 용도, 최종 용도별 - 세계 예측(2025-2030년)

The mRNA Therapeutics Market was valued at USD 33.82 billion in 2023, expected to reach USD 41.99 billion in 2024, and is projected to grow at a CAGR of 24.65%, to USD 158.20 billion by 2030.

mRNA therapeutics refers to the use of messenger RNA to instruct cells to produce proteins that can treat or prevent disease. This rapidly evolving field leverages the natural process of protein synthesis in human cells to address a variety of health conditions, ranging from infectious diseases, such as COVID-19, to non-communicable diseases like cancer. The necessity of mRNA therapeutics lies in its potential for rapid development, scalability, and versatility, which have already been demonstrated in the swift response to the COVID-19 pandemic with effective vaccines. The primary application and end-use scope encompass vaccinations, cancer immunotherapies, and rare genetic disorders, offering a promising outlook for personalized medicine.

Market growth in mRNA therapeutics is significantly influenced by technological advancements, increased funding from public and private sectors, and strategic collaborations between biotech firms and pharmaceutical companies. The recent success of mRNA vaccines has spurred interest and investment, leading to potential opportunities in expanding mRNA-based treatments beyond infectious diseases. Recommendations to capitalize on these opportunities include investing in robust R&D infrastructures, forging strategic alliances, and focusing on regulatory pathways to facilitate market entry.

Challenges curbing market growth involve the high cost of development, storage and distribution complexities due to mRNA's inherent instability, and regulatory hurdles in proving long-term safety and efficacy. Additionally, manufacturing capacity constraints and intellectual property disputes present significant barriers.

Innovation and research should target optimization of mRNA stability and delivery systems, improvement in the precision of targeting specific cells or tissues, and reducing production costs. The nature of the mRNA therapeutics market is characterized by rapid technological changes, strong competition, and highly dynamic regulatory requirements. Collaborations with academia and research institutions can provide valuable insights and drive forward-thinking strategies in this highly promising field.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving mRNA Therapeutics Market

The mRNA Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing incidence of chronic and infectious diseases
  • Growing demand for cancer vaccines and treatments
  • Upsurge demand for mRNA therapeutics and proliferation of government initiatives for large scale sequencing projects
• Market Restraints
  • High cost of research and threat of failure in quantification of mRNA
• Market Opportunities
  • Significant biotechnology-related research and development (R&D) initiatives and advancements in medical technology
  • Development of personalized therapeutics for cancer with strong pipeline of new products
• Market Challenges
  • Regulatory concerns and strategies for mRNA therapeutics

Porter's Five Forces: A Strategic Tool for Navigating the mRNA Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the mRNA Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the mRNA Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the mRNA Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the mRNA Therapeutics Market

A detailed market share analysis in the mRNA Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the mRNA Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the mRNA Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the mRNA Therapeutics Market

A strategic analysis of the mRNA Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the mRNA Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abogen Biosciences, Alnylam Pharmaceuticals, Inc., Arcturus Therapeutics, AstraZeneca plc, BioNTech SE, CRISPR Therapeutics AG, Deep Genomics, Eli Lilly and Company, GSK plc, Laronde Inc., Moderna, Inc., Nutcracker Therapeutics, Inc., Sangamo Therapeutics, Inc., Sarepta Therapeutics, Inc., Tracxn Technologies Limited, and Translate Bio, Inc. by Sanofi S.A..

Market Segmentation & Coverage

This research report categorizes the mRNA Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Prophylactic Vaccines, Therapeutic Drugs, and Therapeutic Vaccines.
• Based on Application, market is studied across Infectious Diseases, Oncology, Rare Genetic Diseases, and Respiratory Diseases.
• Based on End Use, market is studied across Hospitals & Clinics and Research Organizations.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing incidence of chronic and infectious diseases
    • 5.1.1.2. Growing demand for cancer vaccines and treatments
    • 5.1.1.3. Upsurge demand for mRNA therapeutics and proliferation of government initiatives for large scale sequencing projects
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of research and threat of failure in quantification of mRNA
  • 5.1.3. Opportunities
    • 5.1.3.1. Significant biotechnology-related research and development (R&D) initiatives and advancements in medical technology
    • 5.1.3.2. Development of personalized therapeutics for cancer with strong pipeline of new products
  • 5.1.4. Challenges
    • 5.1.4.1. Regulatory concerns and strategies for mRNA therapeutics
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. mRNA Therapeutics Market, by Type

• 6.1. Introduction
• 6.2. Prophylactic Vaccines
• 6.3. Therapeutic Drugs
• 6.4. Therapeutic Vaccines

7. mRNA Therapeutics Market, by Application

• 7.1. Introduction
• 7.2. Infectious Diseases
• 7.3. Oncology
• 7.4. Rare Genetic Diseases
• 7.5. Respiratory Diseases

8. mRNA Therapeutics Market, by End Use

• 8.1. Introduction
• 8.2. Hospitals & Clinics
• 8.3. Research Organizations

9. Americas mRNA Therapeutics Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific mRNA Therapeutics Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa mRNA Therapeutics Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abogen Biosciences
• 2. Alnylam Pharmaceuticals, Inc.
• 3. Arcturus Therapeutics
• 4. AstraZeneca plc
• 5. BioNTech SE
• 6. CRISPR Therapeutics AG
• 7. Deep Genomics
• 8. Eli Lilly and Company
• 9. GSK plc
• 10. Laronde Inc.
• 11. Moderna, Inc.
• 12. Nutcracker Therapeutics, Inc.
• 13. Sangamo Therapeutics, Inc.
• 14. Sarepta Therapeutics, Inc.
• 15. Tracxn Technologies Limited
• 16. Translate Bio, Inc. by Sanofi S.A.